Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereof
US12091468B2 · kind B2 · utility
0Cited by
13References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 15, 2023 |
| Grant date | Sep 17, 2024 |
| Priority date | — |
| Expiry date | Aug 15, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Isolated monoclonal antibodies and antigen-binding fragments thereof are provided that specifically bind to an epitope within the serine protease domain of human MASP-2. In some embodiments, the antibodies or antigen-binding fragments thereof inhibit lectin pathway complement activation. Also provided are polynucleotides encoding the disclosed monoclonal antibodies or antigen-binding fragments thereof, and cloning vectors or expression cassettes comprising such polynucleotides. Further provided are methods of inhibiting lectin pathway complement activation and methods of treating lectin pathway diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.